Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)

Huiqiang Huang, Wenyu Li, Liqun Zou, Yajun Li, Fang Zhu, Keshu Zhou, Yun Liang, Meifang Zheng, Zengjun Li, Hongmei Jing, Wei Yang, Pengcheng He, Kaiyang Ding, Yuhua Li, Mengling Zhong, Ziyi Liu, Liping Su

Blood (2025) 146 (Supplement 1): 8238.

https://doi.org/10.1182/blood-2025-8238

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma

Min Yang, Yang Liang, Guorong Wang, Baijun Fang, Luqun Wang, Songfu Jiang, Yafei Wang, Heng Mei, Wei Yang, Yanjuan He, Wei Wang, Haichao Zhang, Houguo Wang, Jie Jin, Wenming Chen

Blood (2025) 146 (Supplement 1): 5822.

https://doi.org/10.1182/blood-2025-5822

Published: 2025

Journal Articles

NUP98-rearranged pediatric AML is sustained by a conserved leukemia stem cell program with SPNS2/3 as a targetable vulnerability

Jihye Yoon, Elisabeth Denby, Wei Yang, Run Zhang, Masayuki Umeda, Tingting Hu, Jonny Mendoza-Castrejon, Yanan Li, Emily Casey, Riddhi Patel, J. Michael White, Jeffery Klco, Jeffrey Magee

Blood (2025) 146 (Supplement 1): 5002.

https://doi.org/10.1182/blood-2025-5002

Published: 2025

Journal Articles

Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma

Blood (2025) 146 (Supplement 1): 1824.

https://doi.org/10.1182/blood-2025-1824

Published: 2025

Journal Articles

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Blood (2025) 146 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2025-1957

Published: 2025

Journal Articles

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

Fei Li, Stephen Opat, Dengju Li, Keshu Zhou, Peng Liu, Wei Yang, Chan Cheah, Tingyu Wang, Yu Yang, Caixia Li, Hongmei Jing, Henry Ngu, Lipeng Chen, Ting Deng, Fangjie Xie, Naisargee Shah, Zhao Xu, Richard Delarue, Jianyong Li

Blood (2025) 146 (Supplement 1): 1910.

https://doi.org/10.1182/blood-2025-1910

Published: 2025

Journal Articles

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

Ting Niu, Lin LIU, Huijing Wu, Keshu Zhou, Wei Yang, Li Wang, Shu Cheng, Jie Wang, Jinrong Yang, Fei Li, Shiyong Zhou, Yanhong Tong, Ke Tan, Adrian Rui Liang, linyu yang, Lijuan Chen, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 5415.

https://doi.org/10.1182/blood-2025-5415

Published: 2025

Journal Articles

A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)

Shuhua Yi, Liping Su, Bingzong Li, Zhiming Li, Zhengming Jin, Ming Jiang, Wenjuan Yu, Zengjun Li, Jun Luo, Wei Yang, Fei Li, Cailing Wang, Hui Wu, Qiang Wang, Bing Yu, Jianghua Chen, June Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 1808.

https://doi.org/10.1182/blood-2025-1808

Published: 2025

Journal Articles

Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY4032

Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Jin Lu

Blood (2025) 146 (Supplement 1): 7529.

https://doi.org/10.1182/blood-2025-7529

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Blood (2025) 146 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2025-3587

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Blood (2025) 146 (Supplement 1): 886.

https://doi.org/10.1182/blood-2025-886

Published: 2025

Journal Articles

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Blood (2025) 146 (Supplement 1): 3889.

https://doi.org/10.1182/blood-2025-3889

Published: 2025

Journal Articles

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Qingchi Liu, Lihong Shou, Feng Zhang, Cuicui Wu, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2025) 146 (Supplement 1): 7351.

https://doi.org/10.1182/blood-2025-7351

Published: 2025

Journal Articles

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Ningjing Lin, Keshu Zhou, Quande Lin, Lihua Qiu, Zhiming Li, Wei Yang, Yuerong Shuang, Jian Zhang, Hongyan Tong, Hongmei Jing, Peiqi Zhao, Jing Liu, Hong Li, hongli zhang, Liqiang Fu, Gang Lu, Yuqin Song

Blood (2025) 146 (Supplement 1): 5368.

https://doi.org/10.1182/blood-2025-5368

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 3896.

https://doi.org/10.1182/blood-2025-3896

Published: 2025

Journal Articles

QHRD107 (CDK9 Inhibitor), venetoclax, and azacitidine combination therapy (107VA regimen) in relapsed/refractory Acute Myeloid Leukemia: Data updates and subgroup analysis

Blood (2025) 146 (Supplement 1): 5205.

https://doi.org/10.1182/blood-2025-5205

Published: 2025

Journal Articles

Efficacy and safety results of TQB3909，a novel BCL-2 inhibitor, in combination with azacitidine for patients with myeloid malignancies

Jianxiang Wang, Guanchen Bai, Pengcheng He, Hao Jiang, Fuling Zhou, Wei Yang, Xingli Zhao, Shuning Wei, Zhen Wang, Wenwei Zhu, Lin Geng, Zhihua Zhang, Jianhua Qu, Jie Zhou, Tiejun Gong, Ligen Liu, Junfeng Zhu

Blood (2025) 146 (Supplement 1): 5196.

https://doi.org/10.1182/blood-2025-5196

Published: 2025

Journal Articles

Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients

Blood (2025) 146 (Supplement 1): 908.

https://doi.org/10.1182/blood-2025-908

Published: 2025

Journal Articles

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2025-5677

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12)

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma

NUP98-rearranged pediatric AML is sustained by a conserved leukemia stem cell program with SPNS2/3 as a targetable vulnerability

Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma

JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)

Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY4032

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

QHRD107 (CDK9 Inhibitor), venetoclax, and azacitidine combination therapy (107VA regimen) in relapsed/refractory Acute Myeloid Leukemia: Data updates and subgroup analysis

Efficacy and safety results of TQB3909，a novel BCL-2 inhibitor, in combination with azacitidine for patients with myeloid malignancies

Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients

Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only